This article has been updated from a previous version.

NEW YORK, Sept. 24 (GenomeWeb News) - Merck may eventually own up to 19.9 percent of Genaissance as a  result of a license agreement between the companies in which Genaissance will use its haplotyping technology to develop a Merck antidepressant, said Genaissance CEO Kevin Rakin yesterday in a conference call. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.